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Cancer develops as a result of the loss of self-control mechanisms by a cell; it gains the ability to induce angiogenesis, becomes
immortal and resistant to cell death, stops responding to growth suppressor signals, and becomes capable of invasion andmetastasis.
Sphingolipids—a family of membrane lipids—are known to play important roles in the regulation of cell proliferation, the response
to chemotherapeutic agents, and/or prevention of cancer. Despite the underlying functions of sphingolipids in cancer biology, their
metabolism in different malignant tumors is poorly investigated. Some studies showed marked differences in ceramide content
between the tumor and the respective healthy tissue. Interestingly, the level of this sphingolipid could be either low or elevated,
suggesting that the alterations in ceramidemetabolism in cancer tissuemay depend on the biology of the tumor.These processes are
indeed related to the type of cancer, its stage, and histology status. In this paper we present the unique roles of bioactive sphingolipid
derivative in selected gynecologic malignant and nonmalignant lesions.
1. Introduction
Thedevelopmental profiles of cancer in women can be highly
variable. Malignant and nonmalignant lesions of female
reproductive system may differ significantly in terms of the
degree or type of loss of the self-control mechanisms that
accompanies their development and progression.
Age and lifestyle strongly influence the metabolic path-
ways: angiogenesis, immortality, response to growth suppres-
sor signals, and the capability of invasion and metastasis [1].
In addition, the diagnosis of nonmalignant and malignant
lesions in women is not obvious. Therefore, it is important to
find new markers that could differentiate premalignant neo-
plastic lesions from the malignant ones, as well as enabling
the monitoring of the course of treatment [2, 3].
Sphingolipids serve as an important function in
carcinogenesis. Bioactive sphingolipids, such as ceramide
(CER), glucosylceramide (GlcCer), sphingosine (SPH), and
sphingosine-1-phosphate (S1P), act as bioeffector molecules
and coordinate various aspects of cancer biology, including
apoptosis, cell proliferation, cell migration, senescence,
and inflammation. In turn, these sphingolipid-regulated
processes are crucial in cancer development, progression,
metastasis, and chemoresistance of different type of cancer.
Moreover, some of them can be used as potential biomarkers
for early detection of neoplastic tumors, e.g., ovarian cancer,
thus improving the total survival of patients suffering from
this type of gynecological malignancies [4]. Sphingolipids are
involved in the apoptosis and angiogenesis occurring in the
course of neoplastic changes. For instance, S1P participates in
the angiogenesis and the process of apoptosis in the ovaries
treated with chemotherapy [5–7]. Various analytic methods
have been used in order to determine the sphingolipids
content, among other things; Thin Layer Chromatography
(TLC) followed by Gas Chromatography (GLC) or High
Performance Liquid Chromatography (HPLC) are used,
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often combined with Mass Spectrometry (MS/MS). So far,
LC-MS/MS analysis is the most desired method that ensures
high sensitivity and structural specificity of the assessment
of sphingolipids in small samples of biological material [8].
2. Sphingolipid Metabolic Pathways
Ceramides are one of the major lipid molecules of the
sphingolipid metabolism and they play a distinctive role in
the neoplastic tumor development. They can be generated
through the enzymatic hydrolysis of sphingomyelin by sphin-
gomyelinase. Alternatively, CER can be synthesized de novo
from serine and palmitoyl-CoA (Figure 1) [5]. This is the
first but at the same time the rate-limiting stage catalyzed
by the enzyme serine palmitoyltransferase. As a result, 3-
ketosphinganine is formed, which is directly converted into
sphinganine (SPA). Subsequently, the product is acylated
by ceramide synthase to dihydroceramide and the latter
is converted to ceramide by dihydroceramide desaturase.
Ceramide degradation is mainly caused by deacylation to
SPH by the enzyme ceramidase. On the other hand, SPH
may be reacylated to CER or transformed into sphingosine-
1-phosphate by sphingosine kinase (SPHK) [5, 9]. What is
important, S1Pmay be involved in breast cancer, endometrial
cancer, and ovarian cancer progression [6, 10, 11].
Recent research has revealed that ceramides constitute
an essential antineoplastic factor, since those molecules can
act like lipid tumor suppressors. Their proapoptotic as well
as growth-inhibiting properties have gained much attention
in the field of gynecological oncology. Not only CER, but
also the elevated levels of SPH and SPA may influence the
tumor suppressing processes like apoptosis or differentiation.
Several studies have demonstrated that the incubation of
tumor cell lines withCER analogs causing ceramide accretion
is in line with caspase activation resulting in the apoptosis of
cancer cells [3, 12–16].
In contrast, S1P is regarded as a tumor-promoting
compound involved in cell proliferation, transformation,
inflammation, and angiogenesis.Moreover, an increase in the
expression of sphingosine kinase (SPHK1), an enzyme that
transforms sphingosine into S1P, causes the accumulation of
S1P in the cell, thus promoting carcinogenesis and tumor
formation. S1P, apart frombeing amessenger in cell signaling,
also binds to membrane receptors coupled to a G protein
(S1PRs), which is responsible for the majority of its biological
actions (Figure 2) [5]. There is strong likelihood that large
amounts of S1P produced by the neoplastic tissue stimulate
the ovarian cancer cell proliferation by binding with the
above-mentioned receptor [1, 3, 4]. The dysregulation of
sphingolipid metabolism, such as the overproduction of
ceramides and their conversion to S1P, can trigger neoplasm
development. The imbalance on the CER/S1P axis resulting
in the excessive production of S1P may contribute to the
increased risk of ovarian cancer. Alberg et al. drew an identi-
cal conclusion and reported that the upregulation of bioactive
sphingolipids in lung cancer can also potentially be due to the
dysregulation of S1P metabolism [17]. A rise in the content
of S1P is also observed in endometrial carcinoma. This is
consistentwith the activation of SPHK1 and the accumulation
of sphingosine. It is becoming evident that the S1P/SPHK1
metabolism participates in the main oncogenic mechanisms,
from cell survival or proliferation to the apoptosis prevention.
Interestingly, the S1PRs mentioned above may take effect in
both auto and paracrine manner, since the extracellular level
of S1P has been observed. Accordingly, an elevated level of
S1P in neoplasm tissue does not precisely follow the range of
S1P/SPHK1 pathway stimulation in endometrial carcinoma.
Such data becomes more accessible, as the concentration of
S1P in matrix was higher in endometrial cancer patients,
because of its greater production and export by the neoplastic
tissue [11, 18]. A similar remark was made by Sutphen et al.
regarding subjects with ovarian cancer [19]. On the contrary,
a low serum level of S1P observed in ovarian cancer patients
results from its consumption by biologically aggressive tumor
cells that constantly proliferate [6]. Additionally, the dis-
rupted metabolism of CER and SP1 may be responsible for
the resistance to chemotherapy, which is also caused by the
presence of protein mediators and their signaling actions. As
reported by Gatt et al., the elevated expression of ceramide-
transporting proteins and their intracellular accumulation
coupled with a high level of S1P is a potential cause of
resistance to chemotherapy with platinum derivatives in
ovarian cancer [20].
Recent research has revealed considerable dissimilarities
in CER content between various cancers and particular
healthy tissue, thereby indicating that changes in ceramide
metabolism in neoplasm may depend on the type of tumor
[1, 3, 9, 21]. Our previous study demonstrated that in uterine
leiomyomas the content of basic sphingolipids remains quite
constant. However, the increase in CER level with a concomi-
tant decrease in S1P concentration was observed as compared
to normal uterus [22]. Based on our previous research we
may also speculate that the neoplastic progression towards
more aggressive neoplasms is related to the marked increase
in sphingolipid content. The dysregulations in sphingolipid
metabolism were also observed in malignant lesions of the
female reproductive system, such as endometrial and ovarian
cancer [6, 11]. This claim is supported by the fact that the
content of all measured sphingolipids, ceramide species, and
enzymes catalyzing the transformation to bioactive deriva-
tives was upregulated in the neoplasm tissue. Additionally,
the accumulation of sphinganine and dihydroceramide cou-
pled with the activation of palmitoyltransferase suggests that
ceramides are synthesized de novo [12, 23–25]. This remains
in agreement with other reports that present a remarkably
elevated content of dihydroceramide and an increased level
of SPT in several types of carcinoma. However, the de novo
CER synthesis pathway is not characteristic or obligatory for
all tumors. This thesis has been proposed in the publication
of Carton et al. who demonstrated, with the use of immuno-
histochemistry, that only half of 18 various malignant tissues
expressed elevated SPT subunits [26].
Interestingly, depending on the lengths of lipid chains,
ceramides can play opposing roles in neoplastic tumors.
The analysis of C18-Cer function demonstrated its role in
tumor suppression, while C16-Cer was shown to induce cell
proliferation in ovarian cancer. This indicates how many
factors influence various CER metabolism actions [1, 27–29].
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Figure 1: Metabolism of sphingolipids: serine palmitoyl transferase (SPT), (dihydro)ceramide synthase(CERS), dihydroceramide desaturase
(DES), diacylglycerol (DAG), sphingomyelinases (SMase), SM synthase (SMS), glucosylceramide (GlcCER), glucosylceramide synthase
(GCS), ceramide-1-phosphate (Cer-1-P), ceramide kinase (CK), ceramidases (CDases), sphingosine kinase (SK), cerebrosidase (CRS), and
phosphatases of CER-1-P and S1P (C1PP and S1PP).
High concentration of total ceramide in ovarian cancer
as well as the one we can observe in endometrial carcinoma
seems puzzling in the context of its proapoptotic properties
[9]. The first reasonable explanation is that the activation of
the CER pathway fulfills the demand of proliferating tumor
cells, since ceramides are crucial components of the biological
membranes. Another possible interpretation regarding the
endometrial carcinoma is probably related to the overactiva-
tion of ceramidase, which is supported by the accumulation
of sphingosine [11]. Likewise, in ovarian cancer it is due
to the increased rate of degradation by the same enzyme
[6]. Park et al. described this mechanism by presenting
increased activation of acidic ceramidase in many cancer
patients [30]. Moreover, those growth-arresting features of
CER could be antagonized by more intensive production of
S1P as the ratio S1P/ceramide rather than the presence of each
separate sphingolipid determines a cell’s fate. In endometrial
cancer this ratio remained the same as in the healthy uterine.
Finally, such paradox could also be explained by the fact that
neoplastic cells might develop resistance to ceramide [11].
3. Sphingolipids as Diagnostic Biomarkers
Plasma concentration of selected sphingolipids could be an
essentialmarker in ovarian cancer diagnostics.Newbiomark-
ers for noninvasive testing are urgently needed because of
the shortage of highly specific and sensitive methods for
detecting early ovarian cancer, in particular in respect of the
serous ovarian cancer (SOC), one of the most common types
of ovarian neoplasm, which lacks specific clinical manifesta-
tions at an early stage [31, 32]. Diverse evidence shows the
involvement of sphingolipids in different pathways associated
with their elevated levels (e.g., preterm labor, preeclampsia,
fetal Down syndrome, andmyocardial infarction).Murphy et
al. demonstrated the reduced content of sphingolipids in the
brain tissue of peoplewithDown syndrome.This is associated
with the delayed myelination of neurons in the developing
brain of children with trisomy of chromosome 21, resulting
in their mental retardation [32].
Interestingly, other studies showed that in many human
diseases the metabolism of unique sphingolipids is affected
in plasma, as well as in erythrocytes and platelets [33–35].
Knapp et al. demonstrated that patients with acute myocar-
dial infarction are characterized by a reduction in plasma
S1P and sphinganine-1-phosphate (SA1P) concentrations that
is maintained for as long as 30 days after the infarction,
with only partial recovery two years later [36]. In addition to
plasma, S1P and SA1P are present in high concentrations also
in the blood cells. Until recently, it was thought that platelets
are the main source of plasma sphingoid base-1-phosphates.
Thrombocytes possess highly active SPHKand do not express
S1P lyase activity, which allows them to accumulate S1P. How-
ever, it was demonstrated that human platelets release S1P
only upon activation. Similarly to platelets, thrombocytes are

































Figure 2: The biological mechanism of sphingolipids involved in the regulation of cancer growth and therapy: ceramide-activated protein
phosphatases (CAPP) and diacylglycerol (DAG).
able to incorporate extracellular sphingosine and convert it to
S1P. In addition, erythrocytes donot showmeasurable activity
of S1P-degrading enzymes. However, in contrast to throm-
bocytes, red blood cells secrete S1P and SA1P spontaneously.
Knapp et al. showed that patients with acute myocardial
infarction were characterized by a striking accumulation of
both S1P and SA1P in erythrocytes. A similar, albeit transient,
and less prominent trend was observed in platelets as well
[36–38].
Therefore, the purpose of our previous research was to
analyze how the levels of specific sphingolipids (ceramides,
sphingosine-1-phosphate, sphingosine, and sphinganine) are
changed in serum, red blood cells, and platelets of patients
diagnosedwith advanced serous ovarian cancer (ASOC) [39].
Our observations of a notably higher plasma level of C16-Cer,
C18:1-Cer, and C18-Cer in the advanced ovarian cancer group
were compared with the results of the control one. Similarly,
we noticed a considerably higher concentration of C18:1-Cer
in the erythrocytes in the same examined neoplasm tissue
in contrast to the control group. To establish the diagnostic
potential of the sphingolipids, all significant measurements
were later used in ROC curves. Through the setting of the
threshold values, the prediction of the likelihood of ASOC
wasmade with specific sensitivity and specificity. ROC analy-
ses allow the differentiation of patients with moderate/severe
vs. mild ovarian cancer. We demonstrated a significantly
increased risk of ovarian cancer, as the plasma concentration
of each ceramide was as follows:
C16-Cer > 315.98 ng/100 ml; C18:1-Cer > 4.81 ng/100
ml and C18-Cer > 113.26 ng/100 ml; RBC C18:1-Cer > 0.1
ng/100 ml. Additionally, C16, C18.1, and C18 plasma levels
corresponded with the progression of the tumor: the FIGO
staging and grading [6, 39].
Interestingly, hardly the individual measurement of the
aforementioned CER concentration in plasma differentiates
patients and therefore those ceramides may be useful as
potential biochemical markers. A unique switch into the
carcinogenesis pathways recognized as the elevation of par-
ticular CER concentrations across cut points seems helpful
in taking further steps in the diagnosis. The estimated levels
of plasma C16-Cer, C18:1-Cer, and C18-Cer could be a crucial
factor in making the decision regarding an adequate surgery
or procedure [6, 39], such as a biopsy, which is frequently
performedwhen the tumor is in the development stage III/IV.
Furthermore, our previous research demonstrated different
levels of the total investigated CER in RBC, platelets, and
plasma of patients with ASOC. The results were as follows:
plasma: 4236.4 vs. RBC: 100.1 vs. PLT: 444.1 [ng/100 ml].
The metabolic changes allow us to ascertain that CER are
synthesized de novo. This is due to the raised concentrations
of enzymes catalyzing the conversion to bioactive derivatives,
as well as the accumulation of SPA and dihydroceramide
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in conjunction with the activation of palmitoyltransferase.
Based on this data we may conclude that plasma CER
mostly originate from neoplastic tissue. The constant levels
of selected sphingolipids in the blood cells both in RBC
and in platelets may imply the autonomous control of their
metabolism. This corresponds to the findings of Blachnio-
Zabielska et al. who documented similar stable levels of those
sphingolipids in RBC and PLT with a reduction in the levels
of CER, SPH, and SPA in contrast to S1P in the liver of
rats treated with myriocin [33]. Some of the sphingolipids
are unaltered in the blood cells of patients who suffer from
ASOC due to the high grade of malignancy of this tumor
which produces S1P responsible for cell proliferation, neoan-
giogenesis, and antiapoptotic processes [6, 39]. Presently, an
increasing number of studies are dedicated to markers in the
advanced stages of ovarian cancer [40–45]. One of the most
important factors in the tumor transformation, invasion, and
spreading of cancer cells is angiogenesis. Since there is no data
published, we can consider that carcinoma tissue S1P—as a
proangiogenic factor—stimulates the receptors found on the
endothelial cells located in preexisting capillaries. As a result,
the basement membrane is destroyed owing to the S1P and
protease release which allows endothelial cells to proliferate
into the immediate surroundings. In ovarian cancer, there is
probably a tendency for reduction in S1P release from the
endothelial cells with a subsequent decrease in the plasma
level.
Additionally, the compound of S1P in the described ovar-
ian cancer is decomposed by various unspecific phosphatases,
the activity of which may be increased in this type of tumor.
At the same time, the aggressive biological nature of the above
cancer contributes to the destruction of endothelial cells at
the advanced stages of the disease. We may conclude that,
because of the malignancy of this neoplasm, most of the
described blood cell sphingolipids are used inmany processes
and despite the upper level of platelets, the total levels of
sphingolipids are quite constant [6, 46, 47].
4. Sphingolipid Metabolism and Its Impact on
Cancer Treatment
Undoubtedly, the proposed cut-off values for unique
ceramides may prove practical, since we can refer patients
for chemotherapy or a surgical procedure [6]. The first
method of treatment can sometimes be very limited due
to a cancer’s resistance to chemotherapy [48]. As it has
been already mentioned, ovarian cancer can be caused by
S1P dysregulation and the signaling actions carried out
by protein mediators. On the other hand, in the case of
endometrial carcinoma, the upregulation of SPHK1 may
result in the resistance to doxorubicin and cisplatin, generally
used in the treatment of metastases of this tumor. Other
researchers demonstrated that the tumor’s resistance not
only to chemotherapy, but also to the radiation therapy is
a consequence of the increase in the level of SPHK1. As
regards the endometrial cancer, there is a high probability
that a limited response to chemotherapy is associated
with changed sphingolipid metabolism. Curiously, the
antineoplastic action of these chemotherapeutics depends
to a considerable extent on the rise in plasma ceramide
concentration, primarily resulting from the stimulation of
the de novo synthesis pathway [6]. The activation of this
pathway in endometrial cancer was previously characterized.
It is worth mentioning that the catabolism of CER is
stimulated as SPH is accumulated. We assume that resistance
to chemotherapy in endometrial carcinoma, similarly to
that observed in ovarian cancer, results from the altered
sphingolipid metabolism specified by multiple factors.
From the practical point of view, the previous publications
concerning the identification of new therapies indicate that
decreasing S1P rather than boosting CER concentration
needs to be considered in endometrial carcinoma treatment.
This approach may contribute to the improvement of the
effectiveness of conventional chemotherapeutics [11].
A new therapeutic idea is the suppression of glucosylce-
ramide synthase, which works by attenuating the proapop-
totic activity of ceramide in cancer cells. Researchers suggest
using Glc as a preclinical support for ovarian cancer therapy
[49]. However, the problem results from the analytical meth-
ods that do not allow a direct assessment of the role of gluco-
sylceramide synthase in the course of chronic diseases [50].
From a clinical point of view, bioactive sphingolipids may
be useful for tumor detection at an early stage as potential
biomarkers for ovarian cancer. Sphingolipid metabolism in
benign tumors is poorly investigated, as only very few studies
present data regarding the CER/S1P axis. Nonetheless, the
alterations in CER metabolism play an essential role not
only in malignant (ovarian cancer; endometrial cancer), but
also nonmalignant lesions, such as uterine leiomyomas. In
summary, it must be emphasized that the metabolism of
sphingolipids is related to cancer progression. It is impor-
tant to recognize the crucial role of ceramide in order to
differentiate selected malignant and nonmalignant lesions of
female reproductive system not only in the pathogenesis of
the disease, but also as a potential target of new therapies.
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